Skip to main content

Articles

Page 5 of 15

  1. The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast can...

    Authors: D. G. Evans, E. F. Harkness, A. Howell, M. Wilson, E. Hurley, M. M. Holmen, K. U. Tharmaratnam, A. I. Hagen, Y. Lim, A. J. Maxwell and P. Moller
    Citation: Hereditary Cancer in Clinical Practice 2016 14:8
  2. The editors of Hereditary Cancer in Clinical Practice would like to thank all our reviewers who have contributed to the journal in 2015.

    Authors: Jan Lubinski, Rodney J. Scott, Rolf Sijmons and Sarah M. Theissen
    Citation: Hereditary Cancer in Clinical Practice 2016 14:7
  3. Since the identification of BRCA1 there has only ever been described two bi-allelic mutation carriers, one of whom was subsequently shown to be a mono-allelic carrier. The second patient diagnosed with two BRCA1 ...

    Authors: Michelle Wong-Brown, Mary McPhillips, Margaret Gleeson, Allan D. Spigelman, Cliff J. Meldrum, Susan Dooley and Rodney J. Scott
    Citation: Hereditary Cancer in Clinical Practice 2016 14:6

    The Correction to this article has been published in Hereditary Cancer in Clinical Practice 2022 20:20

  4. Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for the development of breast and/or ovarian cancer. The frequency and spectrum of mutations in these genes has not yet been exam...

    Authors: P. Wojcik, M. Jasiowka, E. Strycharz, M. Sobol, D. Hodorowicz-Zaniewska, P. Skotnicki, T. Byrski, P. Blecharz, E. Marczyk, I. Cedrych, J. Jakubowicz, J. Lubiński, V. Sopik, S. Narod and P. Pierzchalski
    Citation: Hereditary Cancer in Clinical Practice 2016 14:5
  5. Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and ...

    Authors: Wiktor Szatkowski, Paweł Blecharz, Jerzy W. Mituś, Marek Jasiówka, Elżbieta Łuczyńska, Jerzy Jakubowicz and Tomasz Byrski
    Citation: Hereditary Cancer in Clinical Practice 2016 14:4
  6. Gastric cancer (GC) is part of the spectrum of diseases linked to BRCA1 and BRCA2 mutations that increase the risk of breast and ovarian cancer. Data suggesting an increased risk of developing GC among BRCA1 and

    Authors: Małgorzata Ławniczak, Anna Jakubowska, Andrzej Białek, Jan Lubiński, Katarzyna Jaworska–Bieniek, Katarzyna Kaczmarek and Teresa Starzyńska
    Citation: Hereditary Cancer in Clinical Practice 2016 14:3
  7. Breast cancer (BC) is an important public health problem worldwide. In Brazil, breast cancer is the most frequently diagnosed tumor and the leading cause of cancer death in women. Hereditary cancer represents ...

    Authors: Gabriela C. Fernandes, Rodrigo A. D. Michelli, Cristovam Scapulatempo-Neto and Edenir I. Palmero
    Citation: Hereditary Cancer in Clinical Practice 2016 14:2
  8. The role of germline mutations in BRCA1 and BRCA2 genes in the risk of the development of ovarian cancer is clinically well established. BRCA1/2 testing seems to have increasing role in clinical management in pat...

    Authors: Agnieszka Synowiec, Gabriel Wcisło, Lubomir Bodnar, Bohdan Górski, Jolanta Szenajch, Katarzyna Szarlej-Wcisło and Cezary Szczylik
    Citation: Hereditary Cancer in Clinical Practice 2016 14:1
  9. Authors: Tomasz Byrski, Tomasz Huzarski, Rebecca Dent, Elzbieta Marczyk, Marek Jasiowka, Jacek Gronwald, Jerzy Jakubowicz, Cezary Cybulski, Rafal Wisniowski, Dariusz Godlewski, Jan Lubinski and Steven A Narod
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A8

    This article is part of a Supplement: Volume 13 Supplement 2

  10. Authors: Magdalena Muszyńska, Wojciech Marciniak, Katarzyna Jaworska-Bieniek, Katarzyna Kaczmarek, Grzegorz Sukiennicki, Marcin Lener, Katarzyna Durda, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Oleg Oszurek, Cezary Cybulski, Tadeusz Dębniak, Antoni Morawski, Anna Jakubowska and Jan Lubiński
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A7

    This article is part of a Supplement: Volume 13 Supplement 2

  11. Authors: Wojciech Marciniak, Magdalena Muszyńska, Katarzyna Jaworska-Bieniek, Katarzyna Kaczmarek, Grzegorz Sukiennicki, Marcin Lener, Katarzyna Durda, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Oleg Oszurek, Cezary Cybulski, Tadeusz Dębniak, Antoni Morawski, Anna Jakubowska and Jan Lubiński
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A6

    This article is part of a Supplement: Volume 13 Supplement 2

  12. Authors: Grzegorz Sukiennicki, Magdalena Muszyńska, Katarzyna Jaworska-Bieniek, Katarzyna Kaczmarek, Wojciech Marciniak, Marcin Lener, Katarzyna Durda, Tomasz Gromowski, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Oleg Oszurek, Cezary Cybulski, Tadeusz Dębniak, Antoni Morawski, Anna Jakubowska…
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A5

    This article is part of a Supplement: Volume 13 Supplement 2

  13. Authors: Katarzyna Kaczmarek, Magdalena Muszyńska, Katarzyna Jaworska-Bieniek, Wojciech Marciniak, Grzegorz Sukiennicki, Marcin Lener, Katarzyna Durda, Tomasz Gromowski, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Oleg Oszurek, Cezary Cybulski, Tadeusz Dębniak, Antoni Morawski, Anna Jakubowska…
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A4

    This article is part of a Supplement: Volume 13 Supplement 2

  14. Authors: Katarzyna Jaworska-Bieniek, Magdalena Muszyńska, Katarzyna Kaczmarek, Wojciech Marciniak, Grzegorz Sukiennicki, Marcin Lener, Katarzyna Durda, Tomasz Gromowski, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Oleg Oszurek, Cezary Cybulski, Tadeusz Dębniak, Antoni Morawski, Anna Jakubowska…
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A3

    This article is part of a Supplement: Volume 13 Supplement 2

  15. Germ-line mutations in several genes, such as BRCA1 and BRCA2, are known to increase the risk of breast cancer. These heritable mutations are unequally represented among populations with different ethnic backgrou...

    Authors: Ielizaveta Gorodetska, Svitlana Serga, Natalia Levkovich, Tetiana Lahuta, Ludmila Ostapchenko, Serhyi Demydov, Nikolay Anikusko, Valeriy Cheshuk, Ivan Smolanka, Svitlana Sklyar, Serhyi Polenkov, Oleksander Boichenko and Iryna Kozeretska
    Citation: Hereditary Cancer in Clinical Practice 2015 13:19
  16. Authors: Szymon Hryhorowicz, Katarzyna Ziemnicka, Marta Kaczmarek-Rys, Justyna Hoppe-Golebiewska, Andrzej Plawski, Marzena Skrzypczak-Zielinska, Monika Golab, Malgorzata Szkudlarek, Batlomiej Budny, Marek Ruchala and Ryszard Slomsk
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 1):A15

    This article is part of a Supplement: Volume 13 Supplement 1

  17. Authors: Marcin Lener, Anna Wiechowska-Kozlowska, Rodney J Scott, Magdalena Muszynska, Jozef Kladny, Piotr Waloszczyk, Anna Rutkowska, Grzegorz Sukiennicki, Tomasz Gromowski, Katarzyna Jaworska-Bieniek, Thierry van de Wetering, Katarzyna Kaczmarek, Anna Jakubowska and Jan Lubinski
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 1):A14

    This article is part of a Supplement: Volume 13 Supplement 1

  18. Genetic screening in families with high risk to develop colorectal cancer (CRC) prevents incurable disease and permits personalized therapeutic and follow-up strategies. The advancement of next-generation sequ...

    Authors: Michele Simbolo, Andrea Mafficini, Marco Agostini, Corrado Pedrazzani, Chiara Bedin, Emanuele D. Urso, Donato Nitti, Giona Turri, Maria Scardoni, Matteo Fassan and Aldo Scarpa
    Citation: Hereditary Cancer in Clinical Practice 2015 13:18
  19. Screening for BRCA 1 and BRCA 2 mutations has long moved from the research lab to the clinic as a routine clinical genetic testing. BRCA molecular alteration pattern varies among ethnic groups which makes it a...

    Authors: Alexandra Tsigginou, Fotios Vlachopoulos, Iordanis Arzimanoglou, Flora Zagouri and Constantine Dimitrakakis
    Citation: Hereditary Cancer in Clinical Practice 2015 13:17
  20. Approximately 30 % of all breast cancer is at least partly attributed to hereditary factors. Familial breast cancer is often inherited in the context of cancer syndromes. The most commonly mutated genes are BR...

    Authors: Camilla Wendt, Annika Lindblom, Brita Arver, Anna von Wachenfeldt and Sara Margolin
    Citation: Hereditary Cancer in Clinical Practice 2015 13:15
  21. Common genetic variants have been shown to modify BRCA1 penetrance. The aim of this study was to validate these reports in a special cohort of Norwegian BRCA1 mutation carriers that were selected for their extrem...

    Authors: Cecilie Heramb, Per Olaf Ekstrøm, Kukatharmini Tharmaratnam, Eivind Hovig, Pål Møller and Lovise Mæhle
    Citation: Hereditary Cancer in Clinical Practice 2015 13:14
  22. Pancreatic cancer (PancCa) is recognized as a component of many well-described hereditary cancer syndromes. Minimal research has focused on patient needs and experiences living with this risk.

    Authors: Meghan Underhill, Donna Berry, Emily Dalton, Jaclyn Schienda and Sapna Syngal
    Citation: Hereditary Cancer in Clinical Practice 2015 13:13
  23. Advancements in genomic testing have led to the identification of single nucleotide polymorphisms (SNPs) associated with prostate cancer. The clinical utility of SNP tests to evaluate prostate cancer risk is u...

    Authors: Michael J Hall, Karen J Ruth, David YT Chen, Laura M Gross and Veda N Giri
    Citation: Hereditary Cancer in Clinical Practice 2015 13:11
  24. Women who carry a mutation for Lynch syndrome face complex decisions regarding strategies for managing their increased cancer risks. At present, there is limited understanding of the factors influencing women’...

    Authors: Holly Etchegary, Elizabeth Dicks, Kathy Watkins, Sabrina Alani and Lesa Dawson
    Citation: Hereditary Cancer in Clinical Practice 2015 13:10

Annual Journal Metrics